310 related articles for article (PubMed ID: 22959074)
1. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
Ginevri F; Nocera A; Comoli P; Innocente A; Cioni M; Parodi A; Fontana I; Magnasco A; Nocco A; Tagliamacco A; Sementa A; Ceriolo P; Ghio L; Zecca M; Cardillo M; Garibotto G; Ghiggeri GM; Poli F
Am J Transplant; 2012 Dec; 12(12):3355-62. PubMed ID: 22959074
[TBL] [Abstract][Full Text] [Related]
2. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
3. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
5. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
9. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
[TBL] [Abstract][Full Text] [Related]
10. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.
Liefeldt L; Brakemeier S; Glander P; Waiser J; Lachmann N; Schönemann C; Zukunft B; Illigens P; Schmidt D; Wu K; Rudolph B; Neumayer HH; Budde K
Am J Transplant; 2012 May; 12(5):1192-8. PubMed ID: 22300538
[TBL] [Abstract][Full Text] [Related]
11. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
12. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
Cioni M; Nocera A; Innocente A; Tagliamacco A; Trivelli A; Basso S; Quartuccio G; Fontana I; Magnasco A; Drago F; Gurrado A; Guido I; Compagno F; Garibotto G; Klersy C; Verrina E; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
J Immunol Res; 2017; 2017():1747030. PubMed ID: 28367453
[TBL] [Abstract][Full Text] [Related]
13. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
15. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.
Lachmann N; Terasaki PI; Schönemann C
Clin Transpl; 2006; ():171-99. PubMed ID: 18365377
[TBL] [Abstract][Full Text] [Related]
16. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
[TBL] [Abstract][Full Text] [Related]
17. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
[TBL] [Abstract][Full Text] [Related]
18. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
19. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
[TBL] [Abstract][Full Text] [Related]
20. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
